There is no competition for BioClonetics & $ENZC HIV scientific research!!!
Enzolytics Inc (OTCMKTS: ENZC) is making a powerful move up the charts on a massive surge of volume after the Company announced on Sept 15, 2020 the execution of a non-binding LOI to merge with BioClonetics Immunotherapeutics, Inc. a biotech company located in Dallas Texas. BioClonetics is in the final stage of development of a parent monoclonal antibody (“mAbs”) (designated as Clone 3), which is non-toxic and has shown in initial in-vitro testing to be effective against greater than 95% of all strains of HIV. Nothing like this presently exists!